Back to Blog
India's Pharma Boom in 2025: PLI Schemes, Global Demand, and R&D Growth
Introduction
India's pharmaceutical sector is expected to surpass USD 130 billion by 2030, making it one of the fastest-growing global markets. This growth is driven by the Production Linked Incentive (PLI) scheme, which has injected momentum into the domestic production of critical APIs and intermediates.
PLI Scheme Highlights
- Offers incentives of up to 20% on incremental sales of eligible products
- Focuses on building infrastructure for KSMs (Key Starting Materials) and bulk drugs
- Encourages import substitution and reduces dependency on China
Industry Impact in 2025
- Surge in local API manufacturing
- Enhanced investment in R&D and advanced CROs
- Strengthening of India's position as a global pharmaceutical hub
Janus's Strategic Shift
Janus Research Chemicals has expanded its product line and synthesis capacity to align with national goals, focusing on high-purity intermediates and impurity profiling services for export markets.
Conclusion
By aligning our services with national initiatives and global quality standards, Janus is not only supporting India's pharmaceutical ambitions but also delivering value to partners worldwide.
